Events in our system are self-managed.  Group and event managers are encouraged to review privacy and security settings, and adjust them if needed.  If you need assistance please contact Indico Support - contact Help at bottom of page. https://learn.getindico.io/categories/managing/

Apr 1 – 5, 2019
Fairmont Château Laurier Hotel
UTC timezone

High-Purity Actinium-225 Production from Radium-226 using a Superconducting Electron Linac

Not scheduled
15m
Fairmont Château Laurier Hotel

Fairmont Château Laurier Hotel

Speaker

Dr Terry Grimm (Niowave, Inc.)

Description

Niowave is operating a closed-loop cycle to domestically produce high-purity Ac-225 and other alpha emitters from Ra-226 using a superconducting electron linear accelerator. The commercial-scale system will produce 10 Ci per week of Ac-225 from a nitrate-based solution of Ra-226. The electron beam impinges on a photon converter to irradiate the Ra-226, inducing a photon-neutron reaction to Ra-225, which decays to Ac-225. Ac 225 is eluted continuously from the target vessel then centrifugal contactors are used to harvest and purify Ac 225 through a separation cascade. Unlike other production methods, including proton linacs (spallation of Th-232) and proton cyclotrons (Ra-226 bombardment), Niowave’s method does not generate any Ac-227 contamination in the Ac-225 product. Niowave’s superconducting linacs can handle higher production output (>500 Ci per year using a 20 MeV, 210 kW beam) than any other method. Demonstration-scale production of 10 mCi batches of Ac-225 at Niowave’s HQ has begun and will be complete in April 2019. Niowave is in a unique position to quickly take the lead in alpha-emitters for cancer therapy because they have expertise in superconducting electron linacs and an NRC materials license to possess and irradiate Ra-226 while capturing gaseous radioisotopes and progeny. This presentation will focus on Niowave’s scale up plans to full production including radium acquisition, NRC and FDA licensing strategies, and a path to profitability.
Email Address grimm@niowaveinc.com
Presentation Type Contributed Oral

Primary author

Dr Terry Grimm (Niowave, Inc.)

Co-authors

Amanda Grimm (Niowave, Inc.) Mike Zamiara (Niowave, Inc.) Dr William Peters (Niowave, Inc.)

Presentation materials

There are no materials yet.